You are here: Industry Insights > Phesgo

News List

UK cancer centre to offer breast cancer treatment at home pharmatimes
April 29, 2021
The Christie NHS Foundation Trust has become the first cancer centre in the UK to offer the treatment Phesgo, developed by Roche’s Genentech division, for breast cancer at home.
Thousands to benefit from five-minute breast cancer treatment pharmatimes
April 07, 2021
NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as five minutes across the country, following a deal with its manufacturer Roche.
Roche gets EC nod for Phesgo to treat HER2-positive breast cancer pharmaceutical-business-review
December 30, 2020
Roche has secured approval from the European Commission (EC) for its Phesgo to treat early and metastatic HER2-positive breast cancer.
Six new medicines leap towards EU approval pharmatimes
November 17, 2020
The EMA’s human medicines committee (CHMP) recommended six medicines for approval at its November 2020 meeting.
FDA Approves Home-Administered Breast Cancer Treatment americanpharmaceuticalreview
July 09, 2020
The U.S. Food and Drug Administration (FDA) has approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer.
FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional fda
July 06, 2020
The U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body ...
Roche’s breast cancer drug Phesgo secures US regulatory approval pharmaceutical-technology
July 01, 2020
Roche has received approval from the US Food and Drug Administration (FDA) for Phesgo, in combination with intravenous (IV) chemotherapy, to treat early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.